ParkinsonCanadaV1, Main, Curation, bibRecord, 002B30

Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys

Identifieur interne : 002B30 ( Main/Curation ); précédent : 002B29; suivant : 002B31

Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys

Auteurs : Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Paul J. Bedard [Canada]

Source :

Movement disorders [ 0885-3185 ] ; 2005.

RBID : Pascal:05-0387176

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Dyskinésie, Kynurenine 3-monooxygenase, Lévodopa, Animal, Singe, Glutamate.
Wicri :
- topic : Singe.

English descriptors

KwdEn :
- Animal, Dyskinesia, Glutamate, Kynurenine 3-monooxygenase, Levodopa, Monkey, Nervous system diseases, Parkinson disease.

Abstract

Homeostatic interactions between dopamine and glutamate are central to the normal physiology of the basal ganglia. This relationship is altered in Parkinsonism and in levodopa-induced dyskinesias (LID), resulting in an upregulation of corticostriatal glutamalergic function. Kynurenic acid (KYNA), a tryptophan metabolite with antagonist activity at ionotropic glutamate receptors and the capability to inhibit glutamate release presynaplically, might therefore be of therapeutic value in LID. To evaluate this hypothesis, we used a pharmacological tool, the kynurenine 3-hydroxylase inhibitor Ro 61-8048, which raises KYNA levels acutely. Ro 61-8048 was tested in MPTP cynomolgus monkeys with a stable parkinsonian syndrome and reproducible dyskinesias after each dose of levodopa. Serum and CSF concentrations of KYNA and its precursor kynurenine increased dose-dependently after Ro 61-8048 administration, alone or in combination with levodopa. Coadministration of Ro 61-8048 with levodopa produced a moderate but significant reduction in the severity of dyskinesias while maintaining the motor benefit. These results suggest that elevation of KYNA levels through inhibition of kynurenine 3-hydroxylase constitutes a promising novel approach for managing LID in Parkinson's disease.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000892
to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000431
to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000800
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :002E68

Links to Exploration step

Pascal:05-0387176

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys</title>
<author><name sortKey="Samadi, Pershia" sort="Samadi, Pershia" uniqKey="Samadi P" first="Pershia" last="Samadi">Pershia Samadi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Département de Medicine, Université Laval</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gregoire, Laurent" sort="Gregoire, Laurent" uniqKey="Gregoire L" first="Laurent" last="Gregoire">Laurent Gregoire</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rassoulpour, Arash" sort="Rassoulpour, Arash" uniqKey="Rassoulpour A" first="Arash" last="Rassoulpour">Arash Rassoulpour</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Maryland Psychiatric Research Center, University of Maryland School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Guidetti, Paolo" sort="Guidetti, Paolo" uniqKey="Guidetti P" first="Paolo" last="Guidetti">Paolo Guidetti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Izzo, Emanuela" sort="Izzo, Emanuela" uniqKey="Izzo E" first="Emanuela" last="Izzo">Emanuela Izzo</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Newron Pharmaceuticals</s1>
<s2>Bresso</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Newron Pharmaceuticals</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schwarcz, Robert" sort="Schwarcz, Robert" uniqKey="Schwarcz R" first="Robert" last="Schwarcz">Robert Schwarcz</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Maryland Psychiatric Research Center, University of Maryland School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Département de Medicine, Université Laval</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0387176</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0387176 INIST</idno>
<idno type="RBID">Pascal:05-0387176</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000892</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000431</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000800</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000800</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Samadi P:effect:of:kynurenine</idno>
<idno type="wicri:Area/Main/Merge">002E68</idno>
<idno type="wicri:Area/Main/Curation">002B30</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys</title>
<author><name sortKey="Samadi, Pershia" sort="Samadi, Pershia" uniqKey="Samadi P" first="Pershia" last="Samadi">Pershia Samadi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Département de Medicine, Université Laval</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gregoire, Laurent" sort="Gregoire, Laurent" uniqKey="Gregoire L" first="Laurent" last="Gregoire">Laurent Gregoire</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rassoulpour, Arash" sort="Rassoulpour, Arash" uniqKey="Rassoulpour A" first="Arash" last="Rassoulpour">Arash Rassoulpour</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Maryland Psychiatric Research Center, University of Maryland School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Guidetti, Paolo" sort="Guidetti, Paolo" uniqKey="Guidetti P" first="Paolo" last="Guidetti">Paolo Guidetti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Izzo, Emanuela" sort="Izzo, Emanuela" uniqKey="Izzo E" first="Emanuela" last="Izzo">Emanuela Izzo</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Newron Pharmaceuticals</s1>
<s2>Bresso</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Newron Pharmaceuticals</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schwarcz, Robert" sort="Schwarcz, Robert" uniqKey="Schwarcz R" first="Robert" last="Schwarcz">Robert Schwarcz</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Maryland Psychiatric Research Center, University of Maryland School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Département de Medicine, Université Laval</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Dyskinesia</term>
<term>Glutamate</term>
<term>Kynurenine 3-monooxygenase</term>
<term>Levodopa</term>
<term>Monkey</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Kynurenine 3-monooxygenase</term>
<term>Lévodopa</term>
<term>Animal</term>
<term>Singe</term>
<term>Glutamate</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Homeostatic interactions between dopamine and glutamate are central to the normal physiology of the basal ganglia. This relationship is altered in Parkinsonism and in levodopa-induced dyskinesias (LID), resulting in an upregulation of corticostriatal glutamalergic function. Kynurenic acid (KYNA), a tryptophan metabolite with antagonist activity at ionotropic glutamate receptors and the capability to inhibit glutamate release presynaplically, might therefore be of therapeutic value in LID. To evaluate this hypothesis, we used a pharmacological tool, the kynurenine 3-hydroxylase inhibitor Ro 61-8048, which raises KYNA levels acutely. Ro 61-8048 was tested in MPTP cynomolgus monkeys with a stable parkinsonian syndrome and reproducible dyskinesias after each dose of levodopa. Serum and CSF concentrations of KYNA and its precursor kynurenine increased dose-dependently after Ro 61-8048 administration, alone or in combination with levodopa. Coadministration of Ro 61-8048 with levodopa produced a moderate but significant reduction in the severity of dyskinesias while maintaining the motor benefit. These results suggest that elevation of KYNA levels through inhibition of kynurenine 3-hydroxylase constitutes a promising novel approach for managing LID in Parkinson's disease.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B30 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002B30 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:05-0387176
   |texte=   Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys

Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri